Interna Therapeutics

Interna Therapeutics is an innovative biotechnology company that developed a transformational delivery technology for macromolecules. The pioneering technology, named Molecular Nano-Motors (MNMs), is based on a novel mechanism that leverages membrane electrical forces, facilitating entry of charged molecules into cells. With this technology new treatment options become available for a wide range of diseases using difficult to deliver molecules such as oligonucleotide-based drugs (siRNA, ASO). Equipped with full-capacity research facilities and working with leading research organizations, the team of seasoned scientists has demonstrated the therapeutic potential of MNM technology in numerous preclinical studies, with a Phase I study of a COVID-19 drug that began in September 2024. Interna’s innovative spirit and scientific excellence has been recognized by key opinion leaders in the pharma industry and by non-governmental organizations.

Interna Therapeutics has raised $57.55M in total funding across 5 rounds. The company is currently at the Mature stage. Key investors include Bill & Melinda Gates Foundation, Ziegler Meditech Equity Partners, Pontifax.

Interna Therapeutics was founded in 1996 by Ilan Ziv, MD (Co-founder).

Interna Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, with core technologies in Biologicals, Molecules, Materials & Substances, Nanomaterials. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Interna Therapeutics is based in Odem St 5-7, Petah Tikva, Israel, Center District.